Welcome

Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue registration.

As part of the reorganisation of the Group's affairs, the Board are pleased to announce that all resoltions placed before the General Meeting held on 12 September 2011 were duly passed. Further details may be viewed here.

An indexed pdf version of our 2011 Annual Report is now available in our Investors' section.

Renovo Business Strategy

Renovo is well funded and its future strategy is aimed at maximising shareholder value. The Company will consider all options available to it which may include acquisitions and mergers of external companies in addition to realising value where possible from its current portfolio of clinical and preclinical candidates and intellectual property. The directors do not intend to place any restrictions on the nature of the business carried out by potential acquisition and merger targets. Renovo’s cost base is being minimised wherever possible in order to maximise the Company’s available cash.

News, Events and Announcements

No events for this year.

Renovo Group director-linked company buys more shares

Monday, 14 May 2012

Renovo Group (LON:RNVO) said it was notified that on May 10, Kestrel Opportunities acquired 1 million ordinary shares in the company at price of 16.625 pence each.
 
Non-executi...Read more

Renovo ends Prevascar development

Monday, 16 April 2012

Renovo (LON:RNVO) today confirmed that it will now perform any further work on Prevascar following the completion of a clinical trial.

The company say...Read more